Mark Hatherill

Director, South African Tuberculosis Vaccine Initiative (SATVI) University of Cape Town. 

Professor Mark Hatherill is Director and leader of the clinical research team of the South African Tuberculosis Vaccine Initiative (SATVI), a University of Cape Town research group focused on understanding risk for and protection against TB, to develop better vaccines and preventive therapies to impact the global epidemic.

A University of Cape Town medical graduate, he trained as a pediatrician and critical care sub-specialist. He has led several clinical trials of novel TB vaccine candidates in infant, adolescent and adult populations. He is PI of the Regional Prospective Observational Research in Tuberculosis (RePORT) South Africa consortium. His work focuses on the design and implementation of clinical trials of novel TB vaccines and studies of biomarkers of TB risk.